- Home
- ROIC vs SUPN Comparison
ROIC vs SUPN Comparison
Compare ROIC & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIC
- SUPN
- Stock Information
- Founded
- ROIC 2007
- SUPN 2005
- Country
- ROIC United States
- SUPN United States
- Employees
- ROIC N/A
- SUPN N/A
- Industry
- ROIC Real Estate Investment Trusts
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- ROIC Real Estate
- SUPN Health Care
- Exchange
- ROIC Nasdaq
- SUPN Nasdaq
- Market Cap
- ROIC 2.0B
- SUPN 1.9B
- IPO Year
- ROIC N/A
- SUPN 2012
- Fundamental
- Price
- ROIC $17.35
- SUPN $35.57
- Analyst Decision
- ROIC Hold
- SUPN Hold
- Analyst Count
- ROIC 6
- SUPN 1
- Target Price
- ROIC $15.75
- SUPN $36.00
- AVG Volume (30 Days)
- ROIC 3.7M
- SUPN 422.4K
- Earning Date
- ROIC 10-22-2024
- SUPN 11-04-2024
- Dividend Yield
- ROIC 3.46%
- SUPN N/A
- EPS Growth
- ROIC 57.91
- SUPN 130.79
- EPS
- ROIC 0.46
- SUPN 1.07
- Revenue
- ROIC $336,785,000.00
- SUPN $651,972,000.00
- Revenue This Year
- ROIC N/A
- SUPN $7.82
- Revenue Next Year
- ROIC $1.15
- SUPN N/A
- P/E Ratio
- ROIC $37.83
- SUPN $33.25
- Revenue Growth
- ROIC 4.18
- SUPN 6.79
- 52 Week Low
- ROIC $11.87
- SUPN $25.53
- 52 Week High
- ROIC $17.40
- SUPN $39.37
- Technical
- Relative Strength Index (RSI)
- ROIC 72.76
- SUPN 53.46
- Support Level
- ROIC $16.41
- SUPN $35.87
- Resistance Level
- ROIC $17.39
- SUPN $39.37
- Average True Range (ATR)
- ROIC 0.24
- SUPN 1.69
- MACD
- ROIC 0.09
- SUPN 0.03
- Stochastic Oscillator
- ROIC 97.81
- SUPN 36.03
About ROIC Retail Opportunity Investments Corp. (MD)
Retail Opportunity Investments Corp is a self-managed real estate investment trust. The company specializes in the acquisition, ownership and management of necessity-based community and neighborhood shopping centers on the west coast of the United States, anchored by supermarkets and drugstores. The Company's primary business is the ownership, management, and redevelopment of retail real estate properties.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.